Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

Intermittent fasting may reduce the risk of blood clots and cardiovascular disease by inhibiting platelet activation.

State Key Laboratory of Chemical Biology, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China University of ...

Necroptosis is the predominant form of neuronal death after ischemic stroke. This study identifies the deubiquitinating enzyme OTUB2 as a novel regulator of the RIPK1-RIPK3-MLKL necroptotic signaling ...

Boston, USA-based biotech Nimbus Therapeutics today revealed that, along with partner Eli Lilly, it has achieved a ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough ...

Terremoto Biosciences Inc. has synthesized new 3H-imidazo[4,5-b]pyridine compounds acting as RAC-α serine/threonine-protein kinase (AKT1; PKB-α) inhibitors reported to be useful for the treatment of ...

Nimbus Therapeutics, LLC, a biotechnology company that designs and develops medicines leveraging its computational drug discovery engine, has achieved a significant preclinical milestone under its ...

Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...

Healx has dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in patients with neurofibromatosis type 1 (NF1), while the FDA approved SpringWorks Therapeutics’ ...

AI Mobility provider Webus International, steel industry veteran Luda Technology, Chinese ad services provider LZ Technology and ...